Handelsinvest Investeringsforvaltning Trims Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Handelsinvest Investeringsforvaltning trimmed its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 16.0% in the 1st quarter, HoldingsChannel reports. The firm owned 6,648 shares of the specialty pharmaceutical company’s stock after selling 1,264 shares during the quarter. Handelsinvest Investeringsforvaltning’s holdings in Jazz Pharmaceuticals were worth $801,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Rise Advisors LLC lifted its position in Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 203 shares during the period. Cape Investment Advisory Inc. boosted its stake in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after acquiring an additional 292 shares in the last quarter. Headinvest LLC bought a new stake in Jazz Pharmaceuticals during the third quarter worth about $56,000. Assetmark Inc. grew its holdings in Jazz Pharmaceuticals by 37.1% in the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 119 shares during the period. Finally, Newbridge Financial Services Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 254.5% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 468 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 336 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JAZZ shares. Truist Financial restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Piper Sandler upped their price target on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Barclays reduced their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Friday, May 3rd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $188.62.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $105.05 on Wednesday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. Jazz Pharmaceuticals plc has a 1 year low of $103.01 and a 1 year high of $146.70. The company has a market cap of $6.62 billion, a P/E ratio of 21.67, a price-to-earnings-growth ratio of 1.64 and a beta of 0.58. The stock’s fifty day moving average price is $108.80 and its 200-day moving average price is $116.44.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The firm had revenue of $901.98 million during the quarter, compared to analysts’ expectations of $938.99 million. On average, equities analysts forecast that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.